08:17 AM EDT, 03/24/2026 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Tuesday it is collaborating with healthcare platform Viz.ai and the American Heart Association to facilitate early diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM.

The collaboration aims to develop an artificial intelligence-enabled care pathway to help clinicians identify ATTR-CM patients earlier in the course of disease and provide guidance on diagnostic evaluation and referral, Alnylam said.

Financial terms of the collaboration were not provided.

The company said it will pilot AI-enabled detection of ATTR-CM at five health systems in late 2026.